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Paget’s disease of the bone (osteitis deformans) was
first described by Sir James Paget in 1877. It occurs in
three phases of the bone forming process. The initial
phase of Paget’s disease of the bone is characterized by
excessive osteoclastic activity and bone resorption in 
a focal region. This phase is followed by an osteolytic–
osteoblastic phase, during which osteoblasts rapidly
deposit new bone in a chaotic fashion. In the final
phase, the lesions become sclerotic, disorganized and
weaker than normal bone [1].
Aside from osteoporosis, Paget’s disease is the most
common bone disorder in Western countries [2]. The
incidence of this disease varies among different eth-
nicities and areas. In Britain, the overall prevalence was
5% between 1970 and 1977 [3], and declined to 2%
between 1993 and 1995 [4]. In Australia, the prevalence
in people aged over 55 years was 4% [5]. In Italy, the
prevalence is at least 1%, without a trend for a decreas-
ing prevalence [6]. In the Netherlands, the estimated
overall prevalence is 3.6% [7]. In the United States,
the overall prevalence is 0.71% [8]. However, Paget’s
disease of the bone is very rare in Africa and Asia.
The majority of patients with Paget’s disease are
elderly, with an age at diagnosis of usually more than
50 years. It affects both men and women, with a slight
predominance in males. Paget’s disease most com-
monly involves the axial skeleton, but it may affect
any of the bones. Although most patients with Paget’s
disease are asymptomatic, 10–30% of patients experi-
ence bone pain, skeletal deformities, neurologic
symptoms, pathologic fracture, or deafness. Patients
may have only one affected bone or have lesions in
multiple bones; however, new lesions rarely develop
in previously unaffected bones after diagnosis [9].
The most terrible complication of Paget’s disease is
development of osteosarcoma, with an incidence of
about 1%. In addition, Paget’s disease may be associ-
ated with an increased incidence of primary hyper-
parathyroidism [10].
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Paget’s disease of the bone, which is characterized by a focal region of highly exaggerated bone
remodeling, is very rare in Asia. Most patients with Paget’s disease are asymptomatic; they are
normocalcemic and show elevated alkaline phosphatase levels. Hypercalcemia in patients with
Paget’s disease has rarely been reported. We report one Chinese patient with Paget’s disease
involving the maxilla bone with an initial presentation of facial cellulitis. Asymptomatic hyper-
calcemia with a low-normal intact parathyroid hormone level developed 9 years later. After 
clodronate treatment, the level of alkaline phosphatase normalized, but the hypercalcemia did
not respond adequately. After analysis of tumor markers and imaging studies, a clinical diagnosis
of pancreatic adenocarcinoma with multiple hepatic and lung metastases with pleural effusion
was made. We suggest that malignancy-associated hypercalcemia should be considered as one of
the causes of hypercalcemia in patients with Paget’s disease.
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CASE PRESENTATION
A 59-year-old female suffered from general weakness
in December 1988 and came to our hospital for help.
Only elevated levels of alkaline phosphatase (Alk-P)
(715 U/L; normal range, 30–110 U/L) were found at
that time. Liver function tests and levels of calcium
(Ca) and phosphate were within the normal ranges.
She was followed-up for 3 years without a definite
etiologic diagnosis for the elevated level of Alk-P, and
lost to follow-up thereafter.
In June 1995, right facial cellulitis occurred. Skull
X-rays showed multiple focal radio-opaque nodular
shadows at the maxillary bone and skull bone. Alk-P
level was 578 U/L. Complete body bone scan was
performed with Tc-99m MDP, which showed intense
radioactivity in the skull. Surgical intervention was
performed and a biopsy of the right maxilla alveolar
bone revealed Paget’s disease with local fibrous dys-
plasia. As diabetes mellitus was also diagnosed, she
was referred to our clinic for further treatment.
In May 1998, left facial cellulitis was noted after 
a dental procedure. Surgical intervention was per-
formed and a biopsy of the left maxilla revealed Paget’s
disease with focal fibrous dysplasia. The level of Ca
was 2.5 mmol/L (normal range, 2.1–2.6 mmol/L) and
Alk-P was 818 U/L.
Alk-P levels had fluctuated since 1995, with the
highest being 818 U/L in May 1998 and the lowest
being 321 U/L in January 2005 (Figure 1). Despite the
elevated Alk-P levels, the patient was symptom-free.
Ca levels were within the normal range until January
2005, when a high Ca level of 2.9 mmol/L with a low-
normal intact parathyroid hormone (iPTH) level of
1.5pmol/L (normal range, 0.8–7.4pmol/L) were noted.
No evidence of malignancy was found by a survey 
of hypercalcemia. Clodronate 400 mg twice daily was
given for the progressive asymptomatic hypercalce-
mia. With clodronate therapy, Alk-P levels gradually
dropped to 150 U/L, but the level of Ca fluctuated
between 2.5 and 2.9 mmol/L.
Progressive body weight loss and watery diarrhea
developed in March 2006. Abdominal computed to-
mography revealed a pancreatic tumor with multiple
hepatic tumors (Figure 2). Carcinoembryonic antigen
level was 30.51 ng/mL (normal, <3.5 ng/mL) and the
level of CA199 was 6,957 U/mL (normal, < 34 U/mL).
A Tc-99m MDP whole body bone scan showed no bony
metastasis. Pancreatic cancer with multiple hepatic
metastases was impressed. Biopsies for pancreatic
and hepatic tumors were suggested, but the family
requested hospice care and refused invasive pro-
cedures. Multiple lung metastases with pleural effu-
sion developed subsequently. Cytology of the pleural
effusion showed adenocarcinoma.
DISCUSSION
Although it is a common disease in Western countries,
Paget’s disease of the bone is very rare in Chinese pop-
ulations. Wang et al reviewed nine Chinese individuals
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Figure 1. Relationship between time and levels of alkaline phosphatase (Alk-P) and calcium (Ca). 
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with Paget’s disease of the bone reported in the English
literature [11]. Compared with Western cases, the Chi-
nese individuals had no familial cases, no malignant
transformation, more frequent monostotic involvement
(44% vs. 17–31%), more frequent skull involvement
(44% vs. 19%), and a higher frequency of symptomatic
cases (78% vs. 5–23%). The present case was reported
because of the unusual initial presentation of facial
cellulitis [12].
The relationship between Paget’s disease and the
onset of hypercalcemia has rarely been delineated in
the literature. Hypercalcemia in Paget’s disease is rare,
occurring primarily with active, polyostotic disease
and immobilization or dehydration [13]. However, an
increased prevalence of primary hyperparathyroidism
was found [10]. The overall prevalence range of pri-
mary hyperparathyroidism in Paget’s disease is
2.2–6.0%, with a mean of 4.4% [14]. No Chinese indi-
vidual with both Paget’s disease and primary hyper-
parathyroidism has previously been reported. In the
report of 11 cases of concurrent Paget’s disease and pri-
mary hyperparathyroidism without surgery, the levels
of iPTH varied within a wide range from 5.6 to
596 pmol/L, and the corrected plasma Ca levels were
between 2.65 and 3.19mmol/L [14]. Of 19 surgical cases
of Paget’s with primary hyperparathyroidism, the lev-
els of iPTH ranged from 2.9 to more than 500 pmol/L,
and the corrected plasma Ca levels ranged from 2.57
to 3.72 mmol/L [14]. The range of iPTH levels varied
widely, even in the high-normal range, in patients with
Paget’s disease and primary hyperparathyroidism.
Our patient was active in her daily activities at the
initial presence of hypercalcemia (when Ca level was
2.9 mmol/L and iPTH level was 1.49 pmol/L) and
remained ambulatory during most of the follow-up
period. Hypercalcemia in this case was not attributed
to immobilization. The levels of Alk-P kept decreas-
ing in the presence of hypercalcemia. As the levels of
Alk-P reflected the disease activity of Paget’s disease
of the bone, the hypercalcemia in this case was appar-
ently not related to Paget’s disease of the bone. The
low-normal value of iPTH and Alk-P levels were not
compatible with the possibility of primary hyper-
parathyroidism. As no etiology was identified, only
treatment for hypercalcemia was given. After follow-
up for 14 months, symptoms of progressive body
weight loss and watery diarrhea appeared, and a pan-
creatic tumor with multiple hepatic tumors was found.
Finally, we considered that the etiology was tumor-
associated hypercalcemia.
Patients with longstanding Paget’s disease should
be followed-up indefinitely because of the increased
risk of malignant transformation. A tumor can arise in
pagetic bone and may present with soft tissue swelling,
increased pain or a rapidly increasing Alk-P. Although
malignant transformation was not found in the
reported Chinese individuals, the follow-up durations
were mostly not available, and the longest one reported
was 16 months [11]. After a period of 10 years of follow-
up in the present case, malignancy-associated hyper-
calcemia, rather than malignant transformation of bone
lesion, developed. Because of the patient’s condition
Figure 2. Abdominal computed tomography with contrast reveals: (A) pancreatic body and tail tumor, 7 cm in size, with (B) multiple
hepatic tumors measuring up to 3.5 cm.
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and the family’s request, no pathologic tissue was
obtained to confirm the etiologic diagnosis. From the
analysis of tumor markers and imaging studies, all
attending physicians and consultants reached an
agreement in the clinical diagnosis of pancreatic ade-
nocarcinoma with multiple hepatic and lung metas-
tases with pleural effusion. Although parathyroid
hormone-related peptide was not checked in the pres-
ent case, we considered that malignancy-associated
hypercalcemia was the etiology of the hypercalcemia
based on the low-normal value of iPTH and the above-
mentioned differential diagnosis.
In conclusion, although Paget’s disease of the bone
may be associated with an increased incidence of pri-
mary hyperparathyroidism, the appearance of hyper-
calcemia in patients with Paget’s disease without high
disease activity warrants careful evaluation for the
possibility of malignancy-associated hypercalcemia
or primary hyperparathyroidism.
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